Cytotoxic Chemotherapy for Multiple Endocrine Neoplasia Type 2A in Selected Patients

For patients with Multiple endocrine neoplasia type 2A (MEN2A) who meet specific clinical criteria, systemic cytotoxic chemotherapy represents a treatment option. This approach is reserved for carefully selected patients, and the appropriateness of treatment depends on individual clinical circumstances.

Treatment Approach

The protocol involves combination cytotoxic chemotherapy — specific drug pairings are used, with more than one established regimen available depending on the clinical setting. Complete agent selection, regimen details, and patient criteria are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1089/thy.2014.0335

Single agent or combination cytotoxic chemotherapeutic regimens administered to patients with MTC are characterized by low response rates (15%–20%) of short duration, although they may be indicated in selected patients.
The most effective regimens are combination therapy with doxorubicin and another agent, or 5-fluorouracil and dacarbazine.

View source ↗